A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Summary

This is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with active ankylosing spondylitis.

Timeline

Start

2023-11-22

Primary completion

2025-02-19

Completion

2025-11-07

Outcome

Met primary endpoint

release “在治疗活动性强直性脊柱炎（AS）的关键注册性Ⅲ期临床研究中取得阳性结果，主要疗效终点ASAS20” akesobio.com ↗

Drugs

Indications